218. Alport syndrome Clinical trials / Disease details

Clinical trials : 30 / Drugs : 36 - (DrugBank : 15) / Drug target genes : 8 - Drug target pathways : 46

diseases per page:

Showing 1 to 10 of 30 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05655728 (ClinicalTrials.gov)	January 3, 2023	8/12/2022	Treatment With Metformin in Chinese Children With Alport Syndrome	Efficacy and Safety of Metformin in Alport Syndrome: A Randomized, Double-blind, Placebo-controlled ...	Alport Syndrome;Metformin	Drug: Metformin;Other: Placebo	Peking University First Hospital	NULL	Not yet recruiting	10 Years	18 Years	All	78	Phase 4	NULL
2	NCT05448755 (ClinicalTrials.gov)	November 28, 2022	29/6/2022	A Study of ELX-02 in Patients With Alport Syndrome	A Phase 2 Open Label Pilot Study to Evaluate the Safety and Efficacy of Subcutaneously Administered ...	Alport Syndrome	Drug: ELX-02	Eloxx Pharmaceuticals, Inc.	NULL	Recruiting	6 Years	30 Years	All	8	Phase 2	Australia;United Kingdom
3	NCT05267262 (ClinicalTrials.gov)	June 15, 2022	23/2/2022	Study to Evaluate R3R01 in Patients With Alport Syndromeand Patients With Focal Segmental Glomerulos ...	A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokine ...	Alport Syndrome;Focal Segmental Glomerulosclerosis	Drug: R3R01	River 3 Renal Corp.	NULL	Recruiting	12 Years	N/A	All	50	Phase 2	United States;Belgium;France;Germany;Netherlands;United Kingdom
4	EUCTR2021-000621-27-NL (EUCTR)	22/03/2022	14/12/2021	Safety, efficacy and pharmacokinetics of sparsentan in pediatric subjects with selected kidney disea ...	A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokineti ...	Proteinuric glomerular diseases including:•Focal segmental glomerulosclerosis (FSGS) •Minimal change ...	Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: S ...	Travere Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	57	Phase 2	France;United States;Spain;Poland;Germany;Netherlands;United Kingdom;Italy;Sweden
5	EUCTR2021-000621-27-IT (EUCTR)	11/01/2022	12/10/2021	Safety, efficacy and pharmacokinetics of sparsentan in pediatric subjects with selected kidney disea ...	A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokineti ...	Proteinuric glomerular diseases including:•Focal segmental glomerulosclerosis (FSGS) •Minimal change ...	Product Name: Sparsentan Product Code: [RE-021] INN or Proposed INN: Sparsentan	TRAVERE THERAPEUTICS, INC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	57	Phase 2	France;United States;Spain;Poland;Netherlands;Germany;United Kingdom;Italy;Sweden
6	NCT05133050 (ClinicalTrials.gov)	January 1, 2022	27/10/2021	Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants	Safety and Efficacy of Early Angiotensin-converting Enzyme Inhibition in Patients With Alport Syndro ...	Alport Syndrome	Drug: Ramipril	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	NULL	Not yet recruiting	30 Years	50 Years	All	510	N/A	China
7	EUCTR2021-000621-27-ES (EUCTR)	08/10/2021	27/07/2021	Safety, efficacy and pharmacokinetics of sparsentan in pediatric subjects with selected kidney disea ...	A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokineti ...	Proteinuric glomerular diseases including:•Focal segmental glomerulosclerosis (FSGS) •Minimal change ...	Product Name: Sparsentan Product Code: RE-021 INN or Proposed INN: Sparsentan Other descriptive name: S ...	Travere Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	57	Phase 2	Spain;Netherlands;Germany;United Kingdom;Italy;Sweden;France;United States;Poland
8	NCT04937907 (ClinicalTrials.gov)	September 8, 2021	17/6/2021	Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)	Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndromein China (CHXLAS) ...	Alport Syndrome, X-Linked	Drug: Hydroxychloroquine Sulfate 100 milligram (mg) Tab;Drug: Benazepril hydrochloride 10 milligram (m ...	Shanghai Children's Hospital	NULL	Recruiting	3 Years	18 Years	All	50	Phase 2	China
9	NCT05003986 (ClinicalTrials.gov)	August 12, 2021	29/7/2021	Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases	A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokineti ...	Focal Segmental Glomerulosclerosis;Minimal Change Disease;Immunoglobulin A Nephropathy;IgA Vasculiti ...	Drug: Sparsentan	Travere Therapeutics, Inc.	NULL	Recruiting	1 Year	17 Years	All	57	Phase 2	United States;Germany;Italy;Netherlands;Poland;Spain;United Kingdom
10	NCT04573920 (ClinicalTrials.gov)	February 1, 2021	28/9/2020	Atrasentan in Patients With Proteinuric Glomerular Diseases	A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases	IgA Nephropathy;Focal Segmental Glomerulosclerosis;Alport Syndrome;Diabetic Kidney Disease;Diabetic ...	Drug: Atrasentan	Chinook Therapeutics U.S., Inc.	NULL	Recruiting	18 Years	N/A	All	100	Phase 2	United States;Australia;Italy;Korea, Republic of;Spain;United Kingdom

First Previous1 2 3Next Last